Forty-Eight-Month Monitoring of Disease Activity in Patients with Long-Standing Rheumatoid Arthritis Treated with TNF-α Inhibitors: Time for Clinical Outcome Prediction and Biosimilar vs Biologic Originator Performance.
Matteo ColinaMicheline KhodeirRoberto RimondiniMarco ValentiniFederica CampomoriStefania CorvagliaGabriele CampanaPublished in: Clinical drug investigation (2024)
We conclude that biosimilars of adalimumab and etanercept have equivalent effectiveness over a long period of time compared to their originator drugs, and also that the levels of disease activity after 6 months of tumor necrosis factor-α inhibitors (originator drugs and biosimilars) might predict the response to therapy at 4 years in patients with long-standing rheumatoid arthritis.
Keyphrases
- rheumatoid arthritis
- disease activity
- rheumatoid arthritis patients
- ankylosing spondylitis
- juvenile idiopathic arthritis
- interstitial lung disease
- randomized controlled trial
- systematic review
- systemic lupus erythematosus
- stem cells
- bone marrow
- systemic sclerosis
- mesenchymal stem cells
- newly diagnosed
- ulcerative colitis